Wikipedia

Robert S. Rosenson

Dr. Robert S. Rosenson is a Professor of Medicine and also lending his services as the Director of cardio metabolic disorders at the Icahn School of Medicine at Mount Sinai.[2]

Robert S. Rosenson
Alma mater
Awards
  • Received Foundation of the National Lipid Association 2019 Clinician/Educator Award[1]
Scientific career
InstitutionsIcahn School of Medicine
Website

Education

edit

Dr. Robert S. Rosenson earned his medical degree from Tulane University. He did his residency in internal medicine at the Brigham and women’s hospital, Harvard medical school and obtained a fellowship in cardiovascular medicine at the University of Chicago hospital.[3][4]

Research and career

edit

Dr. Robert S. Rosenson studies the effects of lipid-lowering therapy in different regions of the United States.[5] He researches selective inhibitors of inflammatory pathways such as lipoprotein-associated with phospholipase A2,[6] and also did research on the efficacy and safety of evolocumab in patients with type 2 diabetes mellitus and hypercholesterolemia.[7]

Dr. Robert Rosenson served as the Director of the Preventive Cardiology Center at Rush-Presbyterian-St. Luke’s Medical Center.[8] At the University Of Michigan School Of Medicine, he served as the Director of the lipoprotein disorders and clinical atherosclerosis research.[9] Now, he is currently serving at the Mount Sinai Icahn School of Medicine as a Professor of Medicine.[10]

Awards and honors

edit

Dr. Robert S. Rosenson was the recipient of the 2019 Clinician/Educator Award by the National Lipid Association. Additional awards include the Ground-Breaking Doctors Award from Chicago Magazine,[11] Simon Dack Award,[12] and received the Jan. J. Kellerman Memorial Award in 2016.[13]

He is a fellow of a number of committees include the American College of Cardiology, American College of Physicians, American Heart Association Council on Epidemiology and Prevention, European Society of Cardiology, and National Lipid Association.[14][15]

Publications

edit
  • Robert S. Rosenson, and Christine C. Tangney. "Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction". JAMA Network.[16]
  • Robert S. Rosenson, H. Bryan Brewer, M. John Chapman, Sergio Fazio, M. Mahmood Hussain, Anatol Kontush, Ronald M. Krauss, James D. Otvos, Alan T. Remaley, and Ernst J. Schaefer. "HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events". Journal of clinical chemistry.[17]
  • Robert S. Rosenson, H. Bryan Brewer, W. Sean Davidson, Zahi A. Fayad, Valentin Fuster, James Goldstein, Marc Heller stein, Xian-Cheng Jiang, Michael C. Phillips, Daniel J. Rader, Alan T. Remaley, George H. Roth blat, Alan R. Tall, and Laurent Yvan-Charvet. "Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport". AHA Journals.[18]
  • Robert S Rosenson, Christine C Tangney, and Larry C Casey. "Inhibition of proinflammatory cytokine production by pravastatin". The Lancet. DOI: https://doi.org/10.1016/S0140-6736(98)05917-0 Robert S Rosenson, James D Otvos, and David S Freedman. "Relations of lipoprotein subclass levels and low-density lipoprotein size to the progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial". The American Journal of Cardiology.[19]

References

edit
  1. ^ "rosenson". mountsinai.org.
  2. ^ "Robert Rosenson | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2019-12-18.
  3. ^ "Robert Rosenson | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2019-12-18.
  4. ^ "Robert Rosenson, Cardiovascular Disease Doctor in New York, NY". doctor.webmd.com. Retrieved 2019-12-18.
  5. ^ Ballantyne, Christie M.; Cannon, Christopher; Lemos, James de; Rosenson, Robert; Philip, Kiran; Mues, Katherine; Alam, Shusama; Liu, Yuyin; Bhatt, Deepak L.; Kosiborod, Mikhail (2019-03-12). "Lipid-Lowering Therapy in Different Regions of the United States: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (gould): A Registry of High Cardiovascular Risk Patients in the United States". Journal of the American College of Cardiology. 73 (9 Supplement 1): 1834. doi:10.1016/S0735-1097(19)32440-4. ISSN 0735-1097.
  6. ^ Garg, Parveen K.; Bartz, Traci M.; Norby, Faye L.; Jorgensen, Neal W.; McClelland, Robyn L.; Ballantyne, Christie M.; Chen, Lin Y.; Gottdiener, John S.; Greenland, Philip; Hoogeveen, Ron; Jenny, Nancy S. (2018-03-01). "Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts". American Heart Journal. 197: 62–69. doi:10.1016/j.ahj.2017.11.010. ISSN 0002-8703. PMC 5860682. PMID 29447785.
  7. ^ Rosenson, Robert S.; Daviglus, Martha L.; Reaven, Peter; Pozzilli, Paolo; Bays, Harold; Monsalvo, Maria Laura; Elliott, Mary; Somaratne, Ransi; Handelsman, Yehuda (2018-07-01). "Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia". Diabetes. 67 (Supplement 1): 128–OR. doi:10.2337/db18-128-OR. ISSN 0012-1797. S2CID 90804054.
  8. ^ "Blood Is Less Sticky With Estrogen Replacement Therapy". ScienceDaily. Retrieved 2019-12-18.
  9. ^ "Dr. Rosenson on Cholesterol". Health.com. Retrieved 2019-12-18.
  10. ^ "Robert Rosenson, MD". www.cardiometabolichealth.org. Retrieved 2019-12-18.
  11. ^ "Advisors Committee". HARTIS Pharma. Retrieved 2019-12-18.
  12. ^ "Robert Rosenson, MD". www.cardiometabolichealth.org. Retrieved 2019-12-18.
  13. ^ Dr. Robert Rosenson: Cholesterol therapy in high-risk CHD patients, retrieved 2019-12-18
  14. ^ "Robert S. Rosenson - Chief, Director, Professor of Cardiology, Internal Medicine in New York, New York, United States of America | eMedEvents". www.emedevents.com. Retrieved 2019-12-18.
  15. ^ "Robert S. Rosenson". TMA - Translational Medicine Academy. Retrieved 2019-12-18.
  16. ^ Rosenson, Robert S.; Tangney, Christine C. (1998-05-27). "Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction". JAMA. 279 (20): 1643–1650. doi:10.1001/jama.279.20.1643. ISSN 0098-7484. PMID 9613915.
  17. ^ Rosenson, R. S.; Brewer, H. B.; Chapman, M. J.; Fazio, S.; Hussain, M. M.; Kontush, A.; Krauss, R. M.; Otvos, J. D.; Remaley, A. T.; Schaefer, E. J. (2011-03-01). "HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events". Clinical Chemistry. 57 (3): 392–410. doi:10.1373/clinchem.2010.155333. ISSN 0009-9147. PMID 21266551.
  18. ^ Rosenson Robert S.; Brewer H. Bryan; Davidson W. Sean; Fayad Zahi A.; Fuster Valentin; Goldstein James; Hellerstein Marc; Jiang Xian-Cheng; Phillips Michael C.; Rader Daniel J.; Remaley Alan T. (2012-04-17). "Cholesterol Efflux and Atheroprotection". Circulation. 125 (15): 1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589. PMC 4159082. PMID 22508840.
  19. ^ Rosenson, Robert S.; Otvos, James D.; Freedman, David S. (2002-07-15). "Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial". American Journal of Cardiology. 90 (2): 89–94. doi:10.1016/S0002-9149(02)02427-X. ISSN 0002-9149. PMID 12106834.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Robert_S._Rosenson&oldid=1204147030"